



CASE Opposes 340B PATIENTS Act

Alexandria, Virginia, August 5, 2025 – Today, Gerard Scimeca, Chairman of Consumer Action for a Strong Economy (CASE), issued the following statement in opposition to the introduction of the 340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support (PATIENTS) Act of 2025:

"The 340B PATIENTS Act would significantly expand a wasteful program that has strayed from its original purpose of helping underserved patients access needed medications. By allowing for the unchecked expansion of contract pharmacies, this legislation does nothing to advance the 340B program's original mission and would instead increase costs for consumers while further enriching healthcare middlemen like pharmacy benefit managers (PBMs).

"Since 2010, the number of 340B contract pharmacy arrangements has [exploded by over 12,000%](#) and studies have revealed that the benefits are flowing to corporate bottom lines, not vulnerable patients. Because pharmacies are not required to pass along the savings on 340B drugs, patients can end up paying full price or more while PBMs and large hospital conglomerates pocket the difference.

"This bill doesn't protect 340B — it only exacerbates the abuse of the program. It also ignores how contract pharmacies prioritize wealthier, more affluent areas, diverting resources away from the vulnerable communities the program was designed to support. Moreover, this legislation could fuel billions in increased costs for employers, taxpayers, and state and local governments.

"Put simply, the 340B PATIENTS Act would deepen the program's dysfunction at consumers' expense. In order to protect patients and uphold the original intent of the 340B program, CASE urges lawmakers to oppose this bill and instead pursue reforms that prioritize transparency, accountability, and patient-first solutions."